6.7.12. summary evidence guidelines life-prolonging treatments castrate-resistant disease. summary evidenceletreatment mcrpc influenced treatments patients already exposed to.4 recommendationsstrength ratingensure testosterone levels confirmed < 50 ng/dl diagnosing castrate-resistant pca (crpc).strongcounsel, manage treat patients metastatic crpc (mcrpc) multidisciplinary team.strongtreat patients mcrpc life-prolonging agents.strongoffer mcrpc patients somatic and/or germline molecular testing well testing mismatch repair deficiencies microsatellite instability.strong